RARA CRAFT DATABASE for FDA Medical Devices

FDA Guidance and Notices, November 2025: Final Guidance on Pre-RFDs and Draft ICH Q3E on Extractables and Leachables

日本語版

November 2025 was a month for combination products and for products whose lead center is not obvious. FDA finalized guidance on how to prepare a Pre-Request for Designation (Pre-RFD), used to get early feedback on how a product will be classified and which center will regulate it. On November 25 it issued a draft on where to submit cross-center master files, and on November 28 it released the draft International Council for Harmonisation (ICH) Q3E guideline on extractables and leachables, which also bears on drug-device combination products, along with a separate draft of Class 3 leachable monographs.

In the Federal Register, FDA classified two device types, including an anchored esophageal sheath, and proposed reclassifying nucleic acid-based test systems used with corresponding approved oncology therapeutics. On November 13, it updated its safety communication on choking rescue protocols to describe its actions against the sale of unauthorized choking rescue devices.

Final guidance

Draft guidance

In the Federal Register

Device classification rules

Most of these write a classification decided earlier into the regulations; they do not mean any individual product was authorized that day. "Reclassification" changes a device type's class, and "proposed" marks a proposed rule open for comment.

Safety communications and other updates

Also this month

  • November 6: The Digital Health Advisory Committee met on generative AI-enabled digital mental health medical devices.
  • November 24: FDA withdrew its July 2022 guidance on patient labeling for laser-assisted in situ keratomileusis (LASIK) lasers.

Note: dates are FDA issue dates or Federal Register publication dates. Linked pages may now show a later version.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles